209 related articles for article (PubMed ID: 32273881)
1. Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics.
Dhall A; Patiyal S; Kaur H; Bhalla S; Arora C; Raghava GPS
Front Genet; 2020; 11():221. PubMed ID: 32273881
[TBL] [Abstract][Full Text] [Related]
2. Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
Dhall A; Patiyal S; Kaur H; Raghava GPS
Comput Biol Med; 2023 Dec; 167():107594. PubMed ID: 37918263
[TBL] [Abstract][Full Text] [Related]
3. HLAncPred: a method for predicting promiscuous non-classical HLA binding sites.
Dhall A; Patiyal S; Raghava GPS
Brief Bioinform; 2022 Sep; 23(5):. PubMed ID: 35580839
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigen Class II alleles associated with acral lentiginous melanoma in Mexican Mestizo patients: A case-control study.
Roldan-Marin R; Rangel-Gamboa L; Vega-Memije ME; Hernández-Doño S; Ruiz-Gómez D; Granados J
Indian J Dermatol Venereol Leprol; 2022; 88(5):608-614. PubMed ID: 35138055
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
[TBL] [Abstract][Full Text] [Related]
6. Risk prediction in cutaneous melanoma patients from their clinico-pathological features: superiority of clinical data over gene expression data.
Arora C; Kaur D; Lathwal A; Raghava GPS
Heliyon; 2020 Aug; 6(8):e04811. PubMed ID: 32913910
[TBL] [Abstract][Full Text] [Related]
7. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Correale P; Saladino RE; Giannarelli D; Giannicola R; Agostino R; Staropoli N; Strangio A; Del Giudice T; Nardone V; Altomonte M; Pastina P; Tini P; Falzea AC; Imbesi N; Arcati V; Romeo G; Caracciolo D; Luce A; Caraglia M; Giordano A; Pirtoli L; Necas A; Amler E; Barbieri V; Tassone P; Tagliaferri P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554614
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
9. HLA-DRB1: A new potential prognostic factor and therapeutic target of cutaneous melanoma and an indicator of tumor microenvironment remodeling.
Deng H; Chen Y; Wang J; An R
PLoS One; 2022; 17(9):e0274897. PubMed ID: 36129956
[TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen class I and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma.
Lu Y; Abdou AM; Cerhan JR; Morton LM; Severson RK; Davis S; Cozen W; Rothman N; Bernstein L; Chanock S; Hartge P; Wang SS
ScientificWorldJournal; 2011; 11():2062-70. PubMed ID: 22125456
[TBL] [Abstract][Full Text] [Related]
11. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
Front Oncol; 2022; 12():976224. PubMed ID: 36185176
[TBL] [Abstract][Full Text] [Related]
12. HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.
Campillo JA; Martínez-Escribano JA; Muro M; Moya-Quiles R; Marín LA; Montes-Ares O; Guerra N; Sánchez-Pedreño P; Frías JF; Lozano JA; García-Alonso AM; Alvarez-López MR
Immunogenetics; 2006 Jan; 57(12):926-33. PubMed ID: 16365741
[TBL] [Abstract][Full Text] [Related]
13. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma.
Luongo V; Pirozzi G; Caracò C; Errico S; de Angelis F; Celentano E; Paino F; Chiofalo MG; Luongo M; Mozzillo N; Lombardi ML
Tissue Antigens; 2004 Jul; 64(1):84-7. PubMed ID: 15191529
[TBL] [Abstract][Full Text] [Related]
14. Association of HLA class I and II genes with cutaneous leishmaniasis: a case control study from Sri Lanka and a systematic review.
Samaranayake N; Fernando SD; Neththikumara NF; Rodrigo C; Karunaweera ND; Dissanayake VH
BMC Infect Dis; 2016 Jun; 16():292. PubMed ID: 27301744
[TBL] [Abstract][Full Text] [Related]
15. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients.
Lee JE; Abdalla J; Porter GA; Bradford L; Grimm EA; Reveille JD; Mansfield PF; Gershenwald JE; Ross MI
Ann Surg Oncol; 2002 Jul; 9(6):587-93. PubMed ID: 12095976
[TBL] [Abstract][Full Text] [Related]
16. Prediction of risk scores for colorectal cancer patients from the concentration of proteins involved in mitochondrial apoptotic pathway.
Lathwal A; Arora C; Raghava GPS
PLoS One; 2019; 14(9):e0217527. PubMed ID: 31498794
[TBL] [Abstract][Full Text] [Related]
17. [Establishment and validation of prediction models for human leukocyte antigen haplotypes and human leukocyte antigen genotypes].
Li Y; Du D; Zhang TT; Han Y; Song Y; Yuan XN; Bao XJ; He J
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(11):834-842. PubMed ID: 38462359
[No Abstract] [Full Text] [Related]
18. Association between
Wattanachai P; Amornpinyo W; Konyoung P; Purimart D; Khunarkornsiri U; Pattanacheewapull O; Tassaneeyakul W; Nakkam N
Front Pharmacol; 2023; 14():1248386. PubMed ID: 37795024
[No Abstract] [Full Text] [Related]
19. Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles.
Vesa J; Chaillon A; Wagner GA; Anderson CM; Richman DD; Smith DM; Little SJ
AIDS; 2017 May; 31(8):1149-1158. PubMed ID: 28244954
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
